4//SEC Filing
McCamish Mark Anthony 4
Accession 0001179110-20-009879
CIK 0001012477other
Filed
Sep 17, 8:00 PM ET
Accepted
Sep 18, 4:20 PM ET
Size
7.8 KB
Accession
0001179110-20-009879
Insider Transaction Report
Form 4
McCamish Mark Anthony
Director
Transactions
- Purchase
ADSs
2020-09-16$5.73/sh+118,602$679,969→ 118,602 total(indirect: By LLC) - Purchase
ADSs
2020-09-17$5.83/sh+52,398$305,250→ 171,000 total(indirect: By LLC)
Footnotes (4)
- [F1]The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.25 to $5.895, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F3]Shares held by Matthew 5 LLC. The Mark & Barbara McCamish Family Trust is the sole owner of Matthew 5 LLC, and the Reporting Person serves as its manager.
- [F4]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.68 to $5.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Documents
Issuer
AVADEL PHARMACEUTICALS PLC
CIK 0001012477
Entity typeother
Related Parties
1- filerCIK 0001390798
Filing Metadata
- Form type
- 4
- Filed
- Sep 17, 8:00 PM ET
- Accepted
- Sep 18, 4:20 PM ET
- Size
- 7.8 KB